Proliferation rate (%) | Gemcitabine | P | Oxaliplatin | P | 5-Fluorouracil | P | Nab-paclitaxel | P | Irinotecan | P |
---|---|---|---|---|---|---|---|---|---|---|
Tumor size, cm | ||||||||||
< 4 | 65.3 ± 11.5 | 0.316 | 72.2 ± 27.9 | 0.814 | 66.5 ± 30.0 | 0.684 | 84.8 ± 28.5 | 0.257 | 71.0 ± 26.4 | 0.049 |
≥ 4 | 26.8 ± 88.6 | 67.3 ± 40.2 | 72.8 ± 21.7 | 35.0 ± 97.4 | 15.0 ± 51.9 | |||||
Tumor differentiation | ||||||||||
Well and moderate | 38.5 ± 78.2 | 0.699 | 55.0 ± 28.7 | 0.127 | 61.7 ± 24.6 | 0.292 | 35.3 ± 67.5 | 0.264 | 31.7 ± 46.8 | 0.449 |
Poor | 53.7 ± 51.2 | 84.5 ± 32.6 | 77.7 ± 25.2 | 84.5 ± 76.1 | 54.3 ± 52.7 | |||||
Nerve invasion | ||||||||||
No | 10.3 ± 72.1 | 0.044 | 74.8 ± 26.8 | 0.618 | 71.2 ± 30.2 | 0.848 | 82.7 ± 94.2 | 0.303 | 37.2 ± 56.5 | 0.700 |
Yes | 81.8 ± 24.8 | 64.7 ± 40.4 | 68.2 ± 21.9 | 37.2 ± 40.9 | 48.8 ± 44.8 | |||||
Lymph node metastasis | ||||||||||
No | 30.2 ± 85.7 | 0.491 | 55.4 ± 34.3 | 0.219 | 69.8 ± 34.1 | 0.989 | 21.4 ± 66.3 | 0.128 | 7.4 ± 38.5 | 0.024 |
Yes | 57.4 ± 46.3 | 80.0 ± 30.5 | 69.6 ± 19.7 | 87.4 ± 69.1 | 68.4 ± 40.0 | |||||
TNM stage | ||||||||||
I–IIIA | 18.3 ± 94.0 | 0.305 | 61.0 ± 36.9 | 0.543 | 64.0 ± 36.4 | 0.606 | 13.3 ± 73.6 | 0.122 | − 7.5 ± 22.2 | 0.004 |
IIIB–IV | 60.0 ± 43.5 | 74.1 ± 32.7 | 72.5 ± 20.0 | 83.3 ± 65.1 | 68.3 ± 37.0 |